{"symbol":"REGN","fiscalQuarter":"Q1-2012","reportDate":"2012-04-26","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2012","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 9.04%","keyNumbers":[{"metric":"EPS","actual":"$0.37","expected":"N/A","surprise":"+282.27%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our performance this quarter, especially in EPS.","Our focus remains on innovation and delivering value to patients."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized the importance of continuing to deliver value to patients."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance significantly exceeded expectations, leading to a notable stock increase of 9.04%. Investors reacted positively, likely due to the surprise in earnings despite the lack of revenue data. The management's focus on innovation and patient value suggests a strategic direction that could benefit the company in the long term.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2012 earnings: EPS beat expectations. Stock up 9.04%. Full breakdown."}}